Type 2 diabetes trials in Japan

In Japan 28 Also abroad 1196

28 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Where
Aichi, Fukuoka, Hokkaido, Osaka, Tokyo
Age
18 years and over
People
2,000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07351045 · EU 2025-523104-71-00
Phase 3Taking people
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Where
Aichi, Fukuoka, Hokkaido, Osaka, Tokyo
Age
18 years and over
People
1,600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07351058 · EU 2025-523106-32-00
Phase 3Taking people
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Where
Chūōku, Ichinomiya-shi, Izunokuni-shi, Kamakura-shi, Kawagoe-shi, Kitakyushu-shi, Kyoto, Mito, Nishinomiya-shi, Ōmihachiman, Yokohama
Age
18 years and over
People
500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07776509 · EU 2025-523295-23-00
No phaseTaking people
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
Where
Many Locations
Age
18 years and over
People
50,000 worldwide
Run by
Bayer
See details and how to joinNCT06278207
Phase 3Taking people
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Where
Chuo-ku, Shinjuku-ku, Suita
Age
18 years and over
People
954 worldwide
Run by
Pfizer
See details and how to joinNCT07595549 · EU 2026-525318-75-00
Phase 3Taking people
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Where
Chiyoda-ku, Fukuoka, Iruma, Moriyama, Niigata, Osaka, Saitama, Sendai, Shizuoka, Tokyo, Urayasu
Age
10 years to 17 years
People
170 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07668336 · EU 2025-524811-35-00
Phase 3Taking people
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Where
Chigasaki, Chūōku, Kamakura, Kasuya-gun, Kawaguchi, Kita-ku, Mihama-ku,Chiba City, Naha, Oyama, Setagaya-ku, Sōka, Tsuchiura, Ushiku, Yokohama
Age
18 years and over
People
1,035 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07282600 · EU 2025-523658-15-00
Phase 3Taking people
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Where
Chūōku, Izumisano, Kawasaki, Kisarazu, Kure, Kyoto, Matsuyama, Osaka, Sapporo, Shimonoseki, Wakayama
Age
18 years and over
People
900 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07392190 · EU 2025-523659-73-00
Phase 3Taking people
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Where
Chūōku, Narashino, Sōka, Tsuchiura
Age
18 years and over
People
1,000 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07881458 · EU 2026-527230-31-00
Phase 2Taking people
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Where
Hachiōji, Kamakura-shi, Naka, Narita
Age
18 years and over
People
120 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07783802
Phase 3Not yet taking people in Japan
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
Where
Chiyoda City, Chūōku, Kawasaki, Kin-cho, Kunigami-gun, Nerima-ku, Shinjuku, Shinjuku-ku, Urasoe
Age
18 years and over
People
2,115 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07881432 · EU 2026-526047-34-00
Phase 3Not yet taking people in Japan
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Where
Hamadayama, Suginami-ku, Himeji, Kisarazu, Kōriyama, Kumamoto, Kurume, Osaka, Shinjyuku, Uji
Age
45 years to 64 years
People
3,000 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07900633 · EU 2026-525919-14-00
Phase 3Taking people
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
Where
Chūōku, Fukuoka, Hachioji-shi, Ichikawa-shi, Kamakura-shi, Kishiwada-shi, Kitakyushu, Meguro-ku, Mito, Sapporo, Shinjuku-ku, Soka-shi, Tama-shi, Yamato-shi, Yokohama
Age
18 years and over
People
2,000 worldwide
Run by
AstraZeneca
See details and how to joinNCT07662109 · EU 2025-523941-81-00
Phase 3Taking people
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
Where
Chūōku, Fukuoka, Hachioji-shi, Osaka, Shibuya-ku, Takatsuki-shi
Age
18 years and over
People
2,500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07784725 · EU 2025-523379-41-00
Phase 3Taking people
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Where
Aichi, Kariya, Aichi, Kasugai, Aichi, Nagoya, Chiba, Chiba, Chiba, Ichikawa, Chiba, Matsudo, Chiba, Narashino, Ehime, Matsuyama, Fukuoka, Chikushino, Fukuoka, Fukuoka, Gumma, Maebashi, Gumma, Takasaki, Hiroshima, Hiroshima, Hiroshima, Kure, Hokkaido, Asahikawa, Hokkaido, Sapporo, Hyogo, Nishinomiya, Ibaraki, Higashiibaraki-gun, Ibaraki, Mito, Ibaraki, Naka, Ibaraki, Tsukuba, Ishikawa, Kanazawa, Iwate, Morioka, Kagawa, Kanonji, Kagawa, Takamatsu, Kagoshima, Kagoshima, Kanagawa, Miura-gun, Kanagawa, Sagamihara, Kanagawa, Yokohama, Kochi, Kochi, Kumamoto, Kumamoto, Kumamoto, Kyoto, Kyoto, Miyagi, Sendai, Miyazaki, Miyakonojo, Nagano, Matsumoto, Nagasaki, Nagasaki, Okayama, Okayama, Osaka, Daito, Osaka, Matsubara, Osaka, Moriguchi, Osaka, Osaka, Osaka, Suita, Saitama, Ageo, Saitama, Koshigaya, Saitama, Saitama, Saitama, Tokorozawa, Shizuoka, Fujieda, Shizuoka, Sunto-gun, Tochigi, Shimotsuga-gun, Tochigi, Shimotsuke, Tokushima, Tokushima, Tokyo, Hachioji, Tokyo, Itabashi-ku, Tokyo, Minato-ku, Tokyo, Ota-ku, Toyama, Toyama, Toyoake-shi
Age
18 years and over
People
11,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07064473 · EU 2025-521188-11-00
Phase 3Taking people
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Where
Aira, Chūōku, Fukuoka, Hachioji-shi, Izunokuni-shi, Kumamoto, Nagoya, Nerima-ku, Osaka, Saga, Sapporo, Shinjuku-ku, Suita-shi, Tanabe-shi
Age
18 years and over
People
1,500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07784270
Phase 3Taking people
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
Where
Asahikawa-shi, Chūōku, Kamakura-shi, Koga-shi, Kumamoto, Mitaka-shi, Mito, Miyazaki, Nagoya, Naka, Nishinomiya-shi, Osaka, Sapporo, Takamatsu
Age
18 years and over
People
1,200 worldwide
Run by
AstraZeneca
See details and how to joinNCT07662213 · EU 2025-523933-24-00
Phase 3Taking people
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
Where
Amagasaki-shi, Chūōku, Kasugai-shi, Koga-shi, Maebashi, Minatoku, Naka, Shinjuku-ku, Shizuoka, Suita-shi, Toshima-ku, Yamato-shi, Yokohama
Age
18 years and over
People
4,500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07667803
Phase 3Taking people
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Where
Aki-gun, Kashiwara-shi, Kitakyusyu-shi, Kumamoto, Matsuyama, Meguro-ku, Mitaka-shi, Mito, Naka, Shizuoka, Tsuchiura-shi
Age
18 years to 99 years
People
950 worldwide
Run by
Amgen
See details and how to joinNCT07684144 · EU 2025-524788-19-00
Phase 3Taking people
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Where
Adachi-ku, Chūōku, Fukuoka, Minato, Mitaka, Suita-shi, Tokyo
Age
18 years and over
People
1,980 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07321886 · EU 2025-523657-34-00
Phase 2Taking people
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Where
Chiba-shi, Chiba, Ibaraki, Soka-shi, Saitama, Tokyo
Age
18 years to 75 years
People
270 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07415954 · EU 2025-523260-20-00
Phase 3Taking people
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
Where
Chigasaki-shi, Chikushino-shi, Gifu, Kagoshima, Kitakyushu, Kumamoto, Kyoto, Maebashi, Nagoya, Osaka, Sapporo, Suita-shi, Tachikawa-shi, Toyota-Shi
Age
18 years and over
People
900 worldwide
Run by
AstraZeneca
See details and how to joinNCT07662135 · EU 2025-523940-12-00
Phase 3Taking people
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
Where
Amagasaki-shi, Chiba, Chitose-shi, Chūōku, Koga-shi, Minatoku, Okayama, Oyama-shi, Shinjuku-ku, Zentsuji-shi
Age
18 years and over
People
800 worldwide
Run by
AstraZeneca
See details and how to joinNCT07662044 · EU 2025-523936-37-00
Phase 1Not yet taking people in Japan
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
Where
Fukuoka, Sumida-ku, Toshima City
Age
18 years to 65 years
People
60
Run by
Eli Lilly and Company
See details and how to joinNCT07765511
Phase 3Taking people
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
Where
Asahikawa-shi, Kamakura-shi, Kashiwa-shi, Kobe, Komoro, Kumamoto, Kyoto, Miyazaki, Naka, Sapporo, Yokohama
Age
18 years and over
People
600 worldwide
Run by
AstraZeneca
See details and how to joinNCT07664553 · EU 2025-523935-20-00